Zynex, Inc. in brief
Zynex, Inc. is an unlisted company in the Medical Devices industry, based in Englewood, Colorado, USA. It was founded in 1996. In the year to December 2024 it had sales of $192 M and a net profit of $3 M, about 2 cents of profit for every dollar of sales. Its largest product and service lines by sales in 2024 were Supplies (69%) and Device revenue (31%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Zynex, Inc.
Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.
The company is based in unincorporated Douglas County, Colorado. Thomas Sandgaard serves as the company's CEO.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Zynex, Inc. timeline
- 1999
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2000
- ✎Renamed Ibonzai Com IncFormerly Life Medical Technologies Inc /Ut/.
- 2001
- 🏁· approximateFounded
- ✎Renamed China Global Development IncFormerly Ibonzai Com Inc.
- 2003
- ✎Renamed Arizona Ventures IncFormerly China Global Development Inc.
- ✎Renamed Fox River Holdings IncFormerly Arizona Ventures Inc.
- 2004
- ✎Renamed Zynex Medical Holdings IncFormerly Fox River Holdings Inc.
- 2008
- ✎Renamed Zynex IncFormerly Zynex Medical Holdings Inc.
- 2021
- 💰Record net income of $17 millionFY2021, the highest profit of the 7 years on record.
- 2024
- 💰Record revenue of $192 millionFY2024, the highest of the 7 years on record.
Events of Zynex, Inc. from SEC EDGAR, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Zynex, Inc.
- Acquisitions and changes
- Delisted: it ended its SEC registration (Form 15) on 26 March 2026.
Market cap history
World rank over time
Rank in USA: #3,036 (Jan 2020) · #2,806 (Jan 2021) · #3,329 (Jan 2022) · #2,540 (Dec 2022) · #3,006 (Jul 2023) · #2,782 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -68.4%
- Operating margin
- 3.1%
- Return on equity
- -207.1%
- Liabilities / assets
- 70.7%
- Net debt
- $-15M
- Revenue growth
- +4.4%
- R&D / revenue
- 6.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $192M | +4.4% | $6M | $3M | 1.6% |
| Dec 2023 | $184M | +16.5% | $11M | $10M | 5.3% |
| Dec 2022 | $158M | +21.4% | $23M | $17M | 10.8% |
| Dec 2021 | $130M | +62.6% | $22M | $17M | 13.1% |
| Dec 2020 | $80M | +76.2% | $10M | $9M | 11.3% |
| Dec 2019 | $45M | +42.4% | $11M | $9M | 20.9% |
| Dec 2018 | $32M | +36.2% | $10M | $10M | 29.9% |
| Dec 2017 | $23M | — | $9M | $7M | 31.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $13M | $1M | $12M | $0.09 | — |
| Dec 2023 | $18M | $1M | $17M | $0.27 | — |
| Dec 2022 | $14M | $0M | $13M | $0.44 | — |
| Dec 2021 | $7M | $1M | $6M | $0.44 | — |
| Dec 2020 | $1M | $1M | $-0M | $0.24 | — |
| Dec 2019 | $6M | $0M | $6M | $0.28 | — |
| Dec 2018 | $9M | $1M | $8M | $0.28 | — |
| Dec 2017 | $8M | $0M | $8M | $0.22 | — |
Quarterly results
Latest quarter to Sep 2025: revenue $13M (-73.3% on a year earlier), net income $-43M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2025.
SEC filings
- Mar 26, 20268-KCurrent reportMaterial agreement · Agreement ended · New financial obligation · Unregistered share sale · Change in control · Directors or officers changed · Bylaws amended
- Mar 20, 20268-KCurrent reportBankruptcy
- Feb 19, 20268-KCurrent reportOther events
- Feb 18, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Feb 11, 20268-KCurrent reportBankruptcy
- Feb 2, 20268-KCurrent reportBankruptcy
- Jan 23, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jan 15, 20268-KCurrent reportMaterial agreement · Bankruptcy · New financial obligation
- Dec 18, 20258-KCurrent reportMaterial agreement · Bankruptcy · New financial obligation · Listing notice
- Dec 16, 20258-KCurrent reportMaterial agreement · Bankruptcy · Regulation FD disclosure
- Nov 17, 202510-QQuarterly report · period to Sep 2025
- Nov 17, 20258-KCurrent reportResults of operations
Official filings of Zynex, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $192 M
- Operating income
- $6 M
- Net income
- $3 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $122 M
- Total liabilities
- $86 M
- Total equity
- $36 M
As of December-2024
Insider trading at Zynex, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joshua R. DisbrowDirector | Disposal to the company | -12,499 | — | — | 0 | Form 4 |
| filed | Michael D. CressDirector | Disposal to the company | -12,499 | — | — | 0 | Form 4 |
| filed | Barry D. MichaelsDirector | Disposal to the company | -80,001 | — | — | 0 | Form 4 |
| filed | Joshua R. DisbrowDirector | Disposal to the company | -89,501 | — | — | 0 | Form 4 |
| filed | Michael D. CressDirector | Disposal to the company | -82,501 | — | — | 0 | Form 4 |
| filed | Anna LucsokCHIEF OPERATING OFFICER | Shares withheld for tax | -3,793 | $2.560 | $10 K | 40,856 | Form 4 |
| filed | Anna LucsokCHIEF OPERATING OFFICER | Grant or award | +7,500 | — | — | 64,412 | Form 4 |
| filed | Daniel J. MoorheadCHIEF FINANCIAL OFFICER | Shares withheld for tax | -3,982 | $2.130 | $8 K | 16,273 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Zynex, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Bankruptcy filing: (8-K); (8-K); (8-K); (8-K); (8-K); (8-K)
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0M |
| Q1 2025 | Q1 2025 | $4.9M |
| Q4 2024 | Q4 2024 | $0M |
| Q3 2024 | Q3 2024 | $0M |
| Q2 2024 | Q2 2024 | $2.3M |
| Q1 2024 | Q1 2024 | $13.3M |
| Q4 2023 | Q4 2023 | $13.5M |
| Q3 2023 | Q3 2023 | $14.9M |
| Q2 2023 | Q2 2023 | $6.1M |
| Q1 2023 | Q1 2023 | $3.4M |
| Q4 2022 | Q4 2022 | $6.6M |
| Q3 2022 | Q3 2022 | $9.2M |
| Q4 2021 | Q4 2021 | $0M |
| Q3 2021 | Q3 2021 | $0.5M |
| Q2 2021 | Q2 2021 | $2M |
Trading halts
- 2025-11-26 19:58 UTC, code LUDP, resumed 20:03 UTC
- 2025-11-26 19:42 UTC, code LUDP, resumed 19:47 UTC
- 2025-11-26 18:49 UTC, code LUDP, resumed 18:54 UTC
Fails to deliver
- : 2.6 M shares at $0.13
- : 15,831 shares at $0.19
- : 139,620 shares at $0.29
- : 75,763 shares at $0.28
- : 70,506 shares at $0.26
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Zynex, Inc. scorecard#
Passes 12 of the 17 checks that could be worked out: strongest in shareholder returns (3 of 4), weakest in profitability (3 of 5). Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 6
- ✓Revenue grew in the newest year4.4%Revenue up 4.4% in fiscal 2024.
- ✓Revenue up more than 5% a year over three years13.9%13.9% a year over the three years to fiscal 2024.
- ✓Faster growth over three years than its peers' median13.9%13.9% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year0.09 vs 0.27Diluted EPS 0.09 in fiscal 2024 against 0.27 the year before (report's currency).
- ✗Net income higher than five years earlier$3 M$3 M in fiscal 2024 against $9 M in 2019.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2024.
Profitability3 of 5
- ✓Profitable in the newest year$3 MNet income $3 M in fiscal 2024.
- ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2024.
- ✓Operating margin above its peers' median3.1%3.1% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%7.3%7.3% in fiscal 2024.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier3.1%3.1% in fiscal 2024 against 17.2% in 2021.
Financial health2 of 2
- ✓Short-term assets cover short-term liabilities4.5×Current ratio 4.46 at the end of fiscal 2024.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns3 of 4
- ✓Pays a dividendYesPaid dividends in fiscal 2024.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- ✓Dividends under 75% of net income0.3%Dividends were 0.3% of net income in fiscal 2024.
- ✓Share count up no more than 2% in a year-10.6%Diluted shares down 10.6% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- ✗Free cash flow covers dividends and buybacks$12 MFree cash flow $12 M against $16 M paid out in fiscal 2024.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Zynex, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | 3.1% | -8.2% | |
| Net margin | 1.6% | -10.4% | |
| Return on equity | 7.3% | -16.8% | |
| Revenue growth, 3 years a year | 13.9% | 10.8% | |
| Revenue growth | 4.4% | 10.4% | |
| Free cash flow margin | 6.3% | -1.9% |
6of 8on the Piotroski tests of financial strength
- Revenue has grown 10 years in a row.
- The share count fell 10.6% in the year (buybacks).
Zynex, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 192+4.4%100% | 184+16.5%100% | 158+21.4%100% | 130+62.6%100% | 80+76.2%100% | 45+42.5%100% | 32+36.2%100% | 23+76.0%100% | 13+14.4%100% | 12—100% | |
| Cost of revenue | 39+2.8%20.5% | 38+19.9%20.8% | 32+17.1%20.2% | 27+56.9%21.0% | 17+97.6%21.7% | 8.8+46.0%19.4% | 6.0+25.3%18.9% | 4.8+37.0%20.6% | 3.5−28.8%26.4% | 4.9—42.4% | |
| Research and development | 12+30.4%6.2% | 9.2+29.6%5.0% | 7.1+173%4.5% | 2.6+225%2.0% | 0.8+33.3%1.0% | 0.6+200%1.3% | 0.2+100%0.6% | 0.1−66.7%0.4% | 0.3r0.3+17.2%2.3% | 0.3—2.2% | |
| Selling, general and administrative | — | — | — | — | — | — | 16+60.4%48.6% | 9.7+5.6%41.3% | 9.2−0.3%68.8% | 9.2—78.9% | |
| Selling and marketing | 87−0.1%45.0% | 87+29.1%47.0% | 67+23.6%42.4% | 54+59.1%41.7% | 34+130%42.6% | 15r14+128%32.7% | 6.5—20.4% | — | — | — | |
| General and administrative | 60+24.4%31.4% | 49+34.4%26.3% | 36+37.2%22.8% | 26+43.7%20.2% | 18+70.7%22.9% | 11r12+19.2%23.6% | 9.0—28.2% | — | — | — | |
| Total costs and expenses | 186+7.4%96.9% | 174+28.3%94.2% | 135+25.3%85.5% | 108+54.5%82.8% | 70+103%87.2% | 34+59.7%75.7% | 22+48.7%67.5% | 14+14.3%61.8% | 13—95.2% | — | |
| Operating income | 6.0−44.4%3.1% | 11−53.0%5.8% | 23+2.6%14.5% | 22+118%17.2% | 10−7.4%12.8% | 11+6.7%24.3% | 10+15.9%32.5% | 8.9+1298%38.2% | 0.6—4.8% | −2.5—−21.3% | |
| Interest expense and finance costs | — | — | — | — | — | — | 0.2−89.4%0.5% | 1.5+312%6.2% | 0.4−30.0%2.6% | 0.5—4.3% | |
| Net interest income | — | −1.1—−0.6% | −0.4—−0.3% | −0.1—−0.1% | −0.0—−0.0% | −0.0—−0.0% | −0.2—−0.5% | — | — | — | |
| Other non-operating income (expense) | −2.4−231%−1.2% | 1.8—1.0% | −0.7—−0.5% | −0.1—−0.1% | −0.1−111%−0.1% | 0.9—1.9% | −0.2—−0.5% | −1.5—−6.2% | −0.6—−4.2% | −0.5—−4.4% | |
| Income before tax | 3.6−71.2%1.9% | 13−43.3%6.8% | 22−0.3%14.0% | 22+119%17.1% | 10−15.0%12.7% | 12+16.9%26.3% | 10+36.3%32.0% | 7.5+8821%32.0% | 0.1—0.6% | −3.0—−25.7% | |
| Income tax | 0.6−77.8%0.3% | 2.8−44.7%1.5% | 5.2−0.3%3.3% | 5.2+379%4.0% | 1.1−55.9%1.3% | 2.4+269%5.4% | 0.7+415%2.1% | 0.1+760%0.6% | 0.0—0.1% | −0.1—−0.5% | |
| Net income including minority interests | 3.0−69.2%1.6% | 9.7−42.9%5.3% | 17−0.3%10.8% | 17+88.5%13.1% | 9.1−4.4%11.3% | 9.5−0.6%20.9% | 9.6+29.7%29.9% | 7.4+10574%31.4% | 0.1—0.5% | −2.9—−25.2% | |
| Minority interests' share of net income | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | −0.0—−0.2% | |
| Net income attributable to shareholders | 3.0−69.2%1.6% | 9.7−42.9%5.3% | 17−0.3%10.8% | 17+88.5%13.1% | 9.1−4.4%11.3% | 9.5−0.6%20.9% | 9.6+29.7%29.9% | 7.4+10574%31.4% | 0.1—0.5% | −2.9—−25.0% | |
| Earnings per share, basic | 0.09−66.7%— | 0.27−38.6%— | 0.44−2.2%— | 0.45+87.5%— | 0.24r0.27−17.2%— | 0.290.0%— | 0.29+26.1%— | 0.23—— | 0.00—— | -0.09—— | |
| Earnings per share, diluted | 0.09−66.7%— | 0.27−38.6%— | 0.440.0%— | 0.44+83.3%— | 0.24r0.26−14.3%— | 0.280.0%— | 0.28+27.3%— | 0.22—— | 0.00—— | -0.09—— | |
| Shares, weighted average (basic) | 32−10.2%— | 36−7.6%— | 38+0.4%— | 38+2.8%— | 37r34+14.8%— | 32−0.2%— | 33+1.1%— | 32+2.8%— | 31r31−0.0%— | 31—— | |
| Shares, weighted average (diluted) | 32−10.6%— | 36−7.6%— | 39−0.2%— | 39+2.0%— | 38r35+13.2%— | 34−0.2%— | 34+2.6%— | 33+6.2%— | 31r31−0.0%— | 31—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 40−11.1%32.5% | 45+121%32.6% | 20−52.7%17.3% | 43+8.8%32.0% | 39+179%54.3% | 14+38.6%49.7% | 10+82.0%52.6% | 5.6+2153%62.3% | 0.2+2988%6.0% | 0.0—0.2% | |
| Short-term investments | 0—0.0% | — | — | — | — | — | — | — | — | — | |
| Receivables | 18−32.8%14.8% | 27−23.5%19.6% | 35+22.5%30.1% | 29+107%21.5% | 14+137%19.2% | 5.8+109%20.6% | 2.8+27.7%14.5% | 2.2−27.8%24.5% | 3.0+24.8%74.0% | 2.4—65.6% | |
| Inventory | 14+6.2%11.4% | 13−2.8%9.6% | 13+25.4%11.6% | 11+24.6%8.1% | 8.6+263%12.0% | 2.4+184%8.4% | 0.8+97.9%4.3% | 0.4+295%4.7% | 0.1−64.9%2.6% | 0.3—8.3% | |
| Other current assets | 3.6+8.3%3.0% | 3.3+284%2.4% | 0.9+26.0%0.7% | 0.7−50.0%0.5% | 1.4+337%1.9% | 0.3−44.5%1.1% | 0.6r0.6+187%3.0% | 0.2—2.2% | — | — | |
| Current assets | 75−14.4%61.6% | 88+26.3%64.2% | 70−15.9%59.7% | 83+31.2%62.0% | 63+179%87.3% | 23+57.5%79.8% | 14r14+71.1%74.4% | 8.4+145%93.8% | 3.4+23.7%83.6% | 2.8—74.8% | |
| Property, plant and equipment | 3.1−1.0%2.5% | 3.1+43.2%2.3% | 2.2−0.5%1.9% | 2.2+13.6%1.6% | 1.9+124%2.7% | 0.9+4.8%3.0% | 0.8+336%4.3% | 0.2−67.6%2.1% | 0.6−27.6%14.2% | 0.8—21.7% | |
| Right-of-use (leased) assets | 9.8−21.5%8.0% | 13−2.5%9.1% | 13−21.4%11.0% | 16+173%12.3% | 6.0+56.4%8.3% | 3.8+25.6%13.5% | 3.1r4.0—15.8% | — | — | — | |
| Goodwill | 200.0%16.7% | 200.0%14.9% | 20+0.0%17.5% | 20r20—15.3% | — | — | — | — | — | — | |
| Other intangible assets | 7.2−11.2%5.9% | 8.2−10.0%6.0% | 9.1r9.8−9.1%7.8% | 10.0—7.5% | — | — | — | 0−100%0.0% | 0.0−54.1%0.8% | 0.1—2.0% | |
| Total assets | 122−10.8%100% | 137+17.5%100% | 116−12.6%100% | 133+84.7%100% | 72+155%100% | 28+46.9%100% | 19r16+116%100% | 8.9+118%100% | 4.1+10.7%100% | 3.7—100% | |
| Accounts payable | 7.1−15.9%5.8% | 8.4+50.1%6.2% | 5.6r5.6+18.5%4.8% | 4.7+0.6%3.6% | 4.7r4.7+120%6.5% | 2.1r2.1+38.0%7.6% | 1.6−31.2%8.1% | 2.3r2.2−21.7%25.3% | 2.9+16.2%70.4% | 2.5—67.0% | |
| Debt due within a year | — | — | 5.30.0%4.6% | 5.3—4.0% | — | — | — | — | — | — | |
| Current liabilities | 17−9.0%13.8% | 19−12.1%13.5% | 21−7.8%18.1% | 23+126%17.2% | 10+94.7%14.0% | 5.2−25.6%18.4% | 7.0r6.4+73.4%36.3% | 4.0r4.0−48.0%45.1% | 7.7+2.7%189% | 7.5—204% | |
| Long-term debt | — | — | 5.3−50.1%4.5% | 11—8.0% | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 10−28.4%8.3% | 14+4.7%10.4% | 14−14.6%11.6% | 16+222%11.9% | 4.9+49.9%6.8% | 3.3+10.6%11.6% | 3.0—15.4% | — | — | — | |
| Total liabilities | 86−4.9%70.8% | 91+81.2%66.3% | 50−15.6%43.0% | 59+287%44.5% | 15+77.6%21.2% | 8.6−13.4%30.5% | 10.0r6.9+147%51.7% | 4.0−49.0%45.1% | 7.9+1.6%193% | 7.8—210% | |
| Retained earnings | 30+11.2%24.4% | 27+57.1%19.6% | 17—14.6% | 0−100%0.0% | 23+63.2%32.5% | 14+195%50.8% | 4.9r4.9—25.3% | −2.4—−27.0% | −9.8—−239% | −9.8—−266% | |
| Shareholders' equity | 36−22.6%29.2% | 46−30.5%33.7% | 66−10.2%57.0% | 74+30.0%55.5% | 57+188%78.8% | 20+110%69.8% | 9.4r9.4+87.9%48.7% | 5.0—55.9% | −3.7—−90.8% | −4.0—−108% | |
| Minority interests | — | — | — | — | — | −0.1—−0.3% | −0.1—−0.5% | −0.1—−1.0% | −0.1—−2.2% | −0.1—−2.4% | |
| Total equity | — | — | — | 74+30.0%55.5% | 57+189%78.8% | 20+112%69.5% | 9.3r9.3+89.5%48.3% | 4.9—54.9% | −3.8—−92.9% | −4.1—−110% | |
| Total liabilities and equity | 122−10.8%100% | 137+17.5%100% | 116−12.6%100% | 133+84.7%100% | 72+155%100% | 28+46.9%100% | 19r16+116%100% | 8.9+118%100% | 4.1+10.7%100% | 3.7—100% | |
| Shares outstanding | 32−3.2%— | 33−10.6%— | 37−7.3%— | 40+3.9%— | 38r35+16.6%— | 33+1.6%— | 32−1.5%— | 33+4.8%— | 310.0%— | 31—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 3.0+30.2%1.6% | 2.3−2.0%1.2% | 2.3+43.7%1.5% | 1.6−39.2%1.3% | 2.7+227%3.3% | 0.8+122%1.8% | 0.4+461%1.2% | 0.1−67.0%0.3% | 0.2+53.8%1.5% | 0.1—1.1% | |
| Cash from operating activities | 13−28.4%6.6% | 18+29.2%9.6% | 14+97.8%8.7% | 6.9+750%5.3% | 0.8−87.0%1.0% | 6.3−33.0%13.9% | 9.4+13.9%29.5% | 8.3+367%35.3% | 1.8+419%13.3% | 0.3—2.9% | |
| Capital expenditure | −0.6—−0.3% | −1.2—−0.7% | −0.4—−0.3% | −0.6—−0.5% | −1.0—−1.2% | −0.2—−0.4% | −1.1—−3.4% | −0.1—−0.4% | −0.2—−1.7% | — | |
| Acquisitions, net of cash acquired | — | — | — | −16—−12.3% | — | — | — | — | — | — | |
| Cash from investing activities | −0.6—−0.3% | −1.0—−0.5% | −0.4—−0.3% | −17—−12.7% | −1.0—−1.2% | −0.2—−0.4% | −1.1—−3.4% | −0.1—−0.4% | −0.2−309%−1.7% | 0.1—0.9% | |
| Debt issued | — | — | — | 16—12.2% | — | — | — | — | — | — | |
| Debt repaid | — | −11—−5.8% | −5.3—−3.4% | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | 25+11304%31.5% | 0.2+25.6%0.5% | 0.2+351%0.6% | 0.0—0.2% | 0—0.0% | — | |
| Shares bought back | −16—−8.1% | −38—−20.6% | −26—−16.7% | −2.7—−2.0% | — | −0.2—−0.4% | −3.4—−10.8% | −0.2—−0.9% | 0—0.0% | — | |
| Dividends paid | −0.0—−0.0% | −0.0—−0.0% | −3.6—−2.3% | −0.0—−0.0% | — | −2.3—−5.0% | — | — | — | — | |
| Cash from financing activities | −17−324%−8.9% | 7.6—4.1% | −36−373%−22.6% | 13−48.2%10.1% | 25—31.6% | −2.2—−4.9% | −3.8—−11.8% | −2.9—−12.2% | −1.3—−9.8% | −0.5—−4.3% | |
| Change in cash | −4.9−120%−2.6% | 24—13.3% | −22−753%−14.2% | 3.4−86.3%2.6% | 25+542%31.4% | 3.9−14.3%8.6% | 4.6−14.2%14.3% | 5.3+2125%22.7% | 0.2—1.8% | −0.1—−0.5% | |
| Report | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 108—100% | 13−73.3%100% | 22−55.3%100% | 27−42.9%100% | 46*—100% | 50—100% | 50+11.0%100% | 47+10.3%100% | — | 45—100% | 42—100% | 49—100% | 42—100% | |
| Cost of revenue | 31—28.4% | 5.3−48.1%39.5% | 7.1−29.2%31.7% | 8.4−10.0%31.5% | 10.0*—21.7% | 10—20.4% | 10.0+7.5%20.0% | 9.3+0.3%20.0% | — | 9.3—20.6% | 9.3—22.0% | 9.4*—19.2% | 8.4—20.2% | |
| Selling and marketing | 58—54.1% | 9.5−54.2%71.0% | 13−44.8%57.5% | 17−27.5%63.7% | 19*—41.9% | 21—41.5% | 23+7.5%46.6% | 23+10.1%50.2% | — | 22—48.1% | 21—50.3% | 19*—39.3% | 17—41.5% | |
| General and administrative | 56—51.9% | 12−22.6%88.5% | 13−12.1%57.0% | 14+7.8%54.1% | 17*—37.6% | 15—30.6% | 14+27.3%29.0% | 13+17.0%28.6% | — | 11—25.3% | 11—27.0% | 10*—20.8% | 9.4—22.5% | |
| Total costs and expenses | 176—163% | 57+24.2%429% | 33−31.7%146% | 40−13.8%149% | 47*—101% | 46—92.4% | 48+12.8%95.5% | 46+9.8%98.9% | — | 42—94.0% | 42—99.3% | 39—79.3% | 35—84.2% | |
| Operating income | −68—−62.8% | −44−1256%−329% | −10−562%−46.1% | −13−2595%−49.3% | −0.6*—−1.2% | 3.8—7.6% | 2.2−18.0%4.5% | 0.5+84.9%1.1% | — | 2.7—6.0% | 0.3—0.7% | 10—20.7% | 6.6—15.8% | |
| Net interest income | — | — | — | — | — | — | — | −0.5—−1.1% | — | −0.3—−0.7% | −0.1—−0.2% | −0.1*—−0.2% | −0.1—−0.3% | |
| Other non-operating income (expense) | −3.0—−2.8% | −0.9—−6.7% | −0.8—−3.7% | −0.7—−2.6% | −0.6*—−1.3% | −0.6—−1.3% | −0.6−144%−1.2% | −0.5−139%−1.1% | — | 1.4—3.1% | 1.3—3.1% | −0.4*—−0.8% | −0.2—−0.5% | |
| Income before tax | −71—−65.6% | −45−1512%−336% | −11−788%−49.9% | −14−106254%−51.9% | −1.2*—−2.6% | 3.2—6.4% | 1.6−60.6%3.2% | 0.0−99.2%0.0% | — | 4.1—9.1% | 1.6—3.8% | 9.7*—19.9% | 6.4—15.3% | |
| Income tax | 3.0+16.0%2.8% | −1.9−344%−14.5% | 8.9+2140%40.0% | −3.4−113567%−12.8% | −0.6*−140%−1.2% | 0.8—1.6% | 0.4−46.4%0.8% | 0.0−90.9%0.0% | 1.4−38.1%— | 0.7—1.7% | 0.0—0.1% | 2.3*—4.6% | 1.5—3.6% | |
| Net income including minority interests | −74—−68.4% | −43−1902%−321% | −20−1746%−89.9% | −10−104060%−39.1% | −0.6*—−1.3% | 2.4—4.8% | 1.2−63.7%2.4% | 0.0−99.4%0.0% | — | 3.4—7.5% | 1.6—3.7% | 7.5*—15.3% | 4.9—11.7% | |
| Net income attributable to shareholders | −74—−68.4% | −43−1902%−321% | −20−1746%−89.9% | −10−104060%−39.1% | −0.6*—−1.3% | 2.4—4.8% | 1.2−63.7%2.4% | 0.0−99.4%0.0% | — | 3.4—7.5% | 1.6—3.7% | 7.5—15.3% | 4.9—11.7% | |
| Earnings per share, basic | — | -1.42−2129%— | -0.66−1750%— | -0.33—— | — | 0.07—— | 0.04−55.6%— | 0.00−100%— | — | 0.09—— | 0.04—— | — | 0.13—— | |
| Earnings per share, diluted | — | -1.42−2129%— | -0.66−1750%— | -0.33—— | — | 0.07—— | 0.04−55.6%— | 0.00−100%— | — | 0.09—— | 0.04—— | — | 0.13—— | |
| Shares, weighted average (basic) | 30−4.6%— | 30−4.6%— | 30−4.7%— | 32−2.3%— | — | 32—— | 32−12.8%— | 32−11.9%— | — | 36—— | 37—— | — | 38—— | |
| Shares, weighted average (diluted) | 30−5.5%— | 30−5.5%— | 30−6.0%— | 32−3.7%— | — | 32—— | 32−13.1%— | 33−12.3%— | — | 37—— | 37—— | — | 39—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 13—29.3% | 13−64.7%29.3% | 18−43.4%20.4% | 24−27.4%22.6% | 40−11.1%32.5% | 38—29.9% | 31−47.4%25.3% | 33+95.7%26.0% | 45+121%32.6% | 59—38.5% | 17—15.1% | 20—17.3% | 24—20.4% | |
| Short-term investments | 0—0.0% | 0—0.0% | 0—0.0% | — | 0—0.0% | — | — | — | — | — | — | — | — | |
| Receivables | 6.7—14.8% | 6.7−69.0%14.8% | 10−56.2%12.0% | 14−44.8%13.3% | 18−32.8%14.8% | 22—17.2% | 24−28.4%19.4% | 25−20.7%20.2% | 27−23.5%19.6% | 33—21.6% | 32—28.9% | 35—30.1% | 28—24.6% | |
| Inventory | 12—26.5% | 12−23.7%26.5% | 12−20.7%14.2% | 14−12.6%12.8% | 14+6.2%11.4% | 16—12.5% | 15+7.4%12.6% | 15+9.1%12.3% | 13−2.8%9.6% | 14—9.4% | 14—12.8% | 13—11.6% | 14—12.4% | |
| Other current assets | 5.1—11.2% | 5.1+49.6%11.2% | 5.5+29.9%6.4% | 5.0+18.2%4.7% | 3.6+8.3%3.0% | 3.4—2.7% | 4.2+177%3.5% | 4.2+97.8%3.3% | 3.3+284%2.4% | 1.5—1.0% | 2.1—1.9% | 0.9—0.7% | 1.1—1.0% | |
| Current assets | 37—81.7% | 37−52.8%81.7% | 46−38.5%53.1% | 56−27.7%53.3% | 75−14.4%61.6% | 78—62.2% | 74−31.1%60.8% | 78+19.7%61.8% | 88+26.3%64.2% | 108—70.5% | 65—58.7% | 70—59.7% | 67—58.4% | |
| Property, plant and equipment | 1.3—2.8% | 1.3−59.4%2.8% | 2.9−11.9%3.3% | 3.0−6.1%2.9% | 3.1−1.0%2.5% | 3.2—2.5% | 3.3+37.0%2.7% | 3.2+41.8%2.6% | 3.1+43.2%2.3% | 2.4—1.6% | 2.3—2.1% | 2.2—1.9% | 2.2—1.9% | |
| Right-of-use (leased) assets | 5.8—12.8% | 5.8−44.9%12.8% | 8.9−20.7%10.3% | 9.1−23.1%8.6% | 9.8−21.5%8.0% | 11—8.3% | 11+2.4%9.2% | 12−0.3%9.4% | 13−2.5%9.1% | 11—7.2% | 12—10.7% | 13—11.0% | 14—11.9% | |
| Goodwill | — | — | 200.0%23.7% | 200.0%19.3% | 200.0%16.7% | 20—16.2% | 200.0%16.7% | 200.0%16.2% | 200.0%14.9% | 20—13.4% | 20—18.4% | 20—17.5% | 20—17.7% | |
| Other intangible assets | — | — | 6.8−11.8%7.9% | 7.0−11.5%6.6% | 7.2−11.2%5.9% | 7.5—5.9% | 7.7−10.6%6.3% | 7.9−10.3%6.3% | 8.2−10.0%6.0% | 8.6—5.6% | 8.8—8.0% | 9.1r9.8—7.8% | 9.3—8.1% | |
| Total assets | 45—100% | 45−64.0%100% | 86−29.5%100% | 106−16.2%100% | 122−10.8%100% | 126—100% | 122−20.1%100% | 126+13.7%100% | 137+17.5%100% | 153—100% | 111—100% | 116—100% | 115—100% | |
| Accounts payable | 13—27.6% | 13+34.9%27.6% | 7.3−6.8%8.6% | 8.2−20.9%7.7% | 7.1−15.9%5.8% | 9.3—7.4% | 7.9+32.9%6.5% | 10+82.7%8.2% | 8.4+50.1%6.2% | 5.9—3.9% | 5.7—5.1% | 5.6r5.6—4.8% | 5.1—4.5% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | 5.3—4.8% | 5.3—4.6% | 5.3—4.6% | |
| Current liabilities | 79—174% | 79+297%174% | 74+305%85.9% | 16−25.0%15.4% | 17−9.0%13.8% | 20—15.8% | 18+29.4%15.0% | 22+3.3%17.2% | 19−12.1%13.5% | 14—9.2% | 21—19.0% | 21—18.1% | 20—17.1% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | 4.0—3.6% | 5.3—4.5% | 6.6—5.7% | |
| Lease liabilities (non-current) | 7.2—15.9% | 7.2−35.5%15.9% | 8.2−33.0%9.5% | 9.1−31.0%8.6% | 10−28.4%8.3% | 11—8.9% | 12+1.4%10.0% | 13+3.1%10.4% | 14+4.7%10.4% | 12—7.9% | 13—11.5% | 14—11.6% | 14—12.1% | |
| Total liabilities | 87—191% | 87−4.0%191% | 85−5.0%98.5% | 85−8.7%80.4% | 86−4.9%70.8% | 90—71.6% | 89−1.3%73.1% | 93+100.0%73.8% | 91+81.2%66.3% | 90—59.2% | 47—41.9% | 50—43.0% | 50—43.5% | |
| Retained earnings | −44—−96.1% | −44−243%−96.1% | −0.7−102%−0.8% | 19−27.7%18.3% | 30+11.2%24.4% | 30—24.1% | 28+27.5%23.0% | 27+43.9%21.2% | 27+57.1%19.6% | 22—14.4% | 19—16.8% | 17—14.6% | 9.6—8.3% | |
| Shareholders' equity | −41—−91.3% | −41−216%−91.3% | 1.3−96.2%1.5% | 21−37.2%19.6% | 36−22.6%29.2% | 36—28.4% | 33−47.3%26.9% | 33−48.7%26.2% | 46−30.5%33.7% | 62—40.8% | 64—58.1% | 66—57.0% | 65—56.5% | |
| Total liabilities and equity | 45—100% | 45−64.0%100% | 86−29.5%100% | 106−16.2%100% | 122−10.8%100% | 126—100% | 122−20.1%100% | 126+13.7%100% | 137+17.5%100% | 153—100% | 111—100% | 116—100% | 115—100% | |
| Shares outstanding | 30—— | 30−4.7%— | 30−4.5%— | 30−5.2%— | 32−3.2%— | 32—— | 32−11.9%— | 32−13.0%— | 33−10.6%— | 36—— | 37—— | 37—— | 37—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.1—1.9% | 0.3−58.8%2.4% | 0.6−33.5%2.5% | 0.6−21.4%2.2% | 0.6*—1.4% | 0.8—1.5% | 0.8+28.6%1.7% | 0.7+139%1.6% | — | 0.7r0.7—1.5% | 0.3—0.7% | 0.6*—1.3% | 0.6—1.4% | |
| Cash from operating activities | −21—−19.0% | −6.3*−189%−47.2% | −6.2*−647%−27.8% | −11−608%−39.5% | 2.4*—5.3% | 7.1*—14.2% | 1.1*+53.0%2.3% | 2.1+6.9%4.4% | — | 0.7*—1.6% | 1.9—4.6% | 4.8*—9.7% | 7.4*—17.8% | |
| Capital expenditure | −0.4—−0.4% | −0.0*—−0.1% | −0.0*—−0.1% | −0.2—−0.6% | −0.2*—−0.5% | −0.1*—−0.1% | −0.1*—−0.3% | −0.2—−0.3% | — | −0.2*—−0.5% | −0.2—−0.4% | −0.1*—−0.2% | −0.1*—−0.3% | |
| Cash from investing activities | −0.4—−0.4% | −0.0*—−0.1% | −0.0*—−0.1% | −0.2—−0.6% | −0.2*—−0.5% | −0.1*—−0.1% | −0.1*—−0.3% | −0.2—−0.3% | — | −0.2*—−0.5% | −0.2—−0.4% | −0.1*—−0.2% | −0.1*—−0.3% | |
| Debt repaid | — | — | — | — | — | — | — | — | — | −9.3*—−20.8% | −1.3—−3.2% | −1.3*—−2.7% | −1.3*—−3.2% | |
| Shares bought back | −4.9—−4.6% | 0*—0.0% | 0*—0.0% | −4.9—−18.6% | 0*—0.0% | 0*—0.0% | −2.3*—−4.7% | −13—−28.5% | — | −6.1*—−13.6% | −3.4—−8.0% | −6.6*—−13.6% | −9.2*—−22.1% | |
| Dividends paid | — | — | — | — | 0*—0.0% | −0.0*—−0.0% | 0*—0.0% | −0.0—−0.0% | — | — | — | 0*—0.0% | 0*—0.0% | |
| Cash from financing activities | −3.4—−3.1% | 2.0*—15.3% | −0.1*—−0.4% | −5.1—−19.2% | −0.2*—−0.5% | −0.3*—−0.5% | −3.0*−107%−5.9% | −14—−29.3% | — | 41*—92.2% | −5.1—−12.1% | −8.1*—−16.5% | −11*—−25.6% | |
| Change in cash | −24—−22.5% | −4.3*−164%−32.1% | −6.3*—−28.3% | −16—−59.4% | 2.0*—4.4% | 6.7*—13.5% | −2.0*−105%−3.9% | −12—−25.2% | — | 42*—93.3% | −3.4—−7.9% | −3.4*—−6.9% | −3.3*—−8.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q/A | 10-Q | 10-Q | 10-Q | 10-Q/A | 10-K/A | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Zynex, Inc. sells: revenue by product line, fiscal 2024#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2023. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Supplies$133 M69%+5.8%
- Device revenue$60 M31%+1.3%
Source: SEC annual report (XBRL data) · as of Dec 31, 2024
Events at Zynex, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Bankruptcy or receivershipFiling
- Bankruptcy or receivershipFiling
- Bankruptcy or receivershipFiling
- Bankruptcy or receivershipFiling
- Bankruptcy or receivershipDelisting noticeFiling
- Bankruptcy or receivershipDebt called earlyFiling
And 2 more in the list below.
Bankruptcy or receivership 6 · Delisting notice 1 · Auditor changed 1 · Debt called early 1 · Impairment 1 · Restructuring 1 · Change in control 1 · Directors and officers 8 · Material agreement 5 · Agreement ended 1 · New debt 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Change in controlDirectors and officersMaterial agreementAgreement endedNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Bankruptcy or receivership | 8-K | |
| Material agreement | 8-K | |
| Bankruptcy or receivership | 8-K | |
| Bankruptcy or receivership | 8-K | |
| Directors and officers | 8-K | |
| Bankruptcy or receivershipMaterial agreementNew debt | 8-K | |
| Bankruptcy or receivershipDelisting noticeMaterial agreementNew debt | 8-K | |
| Bankruptcy or receivershipDebt called earlyMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| ImpairmentRestructuring | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Mar 26, 2026
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | 86 | · | · | · | · | · | · | 86 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 86 people | Restructuring planSEC 8-K | “(the “Company”) executed a reduction in its workforce affecting 86 corporate roles, or 14% of the Company’s total number of employees.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Zynex, Inc. compares in Medical Devices
- Revenue$192 M · higher than 53% of 155
- Net margin-68.3% · higher than 20% of 144
- Revenue growth4.4% · higher than 31% of 104
- 🇯🇵 Rion Co., Ltd.$186 M
- 🇺🇸 SI-BONE, Inc.$1.0 B
- 🇺🇸 Cytek Biosciences, Inc.$770 M
- 🇨🇷 Establishment Labs Holdings Inc.$2.1 B
- 🇺🇸 Treace Medical Concepts, Inc.$280 M
- 🇺🇸 AxoGen, Inc.$3.0 B
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Zynex, Inc.🇺🇸 | $366 M | — | -68.3% | +4.4% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Abbott Laboratories$181.1 B
- Medtronic plc$121.2 B
- Stryker Corporation$116.5 B
- Boston Scientific Corporation$66.2 B
- Edwards Lifesciences Corporation$52.8 B
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.$27.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Zynex, Inc.? Verify and update this profile — free
Show Zynex, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.